Case Report
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Transplant. Mar 18, 2025; 15(1): 96696
Published online Mar 18, 2025. doi: 10.5500/wjt.v15.i1.96696
Success of intravenous immunoglobulin and steroids in managing severe COVID-19 following lung transplantation: A case report
Yen-Shou Kuo, Kuan-Hsun Lin, Ying-Yi Chen, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang
Yen-Shou Kuo, Kuan-Hsun Lin, Ying-Yi Chen, Yuan-Ming Tsai, Ti-Hui Wu, Hsu-Kai Huang, Tsai-Wang Huang, Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114202, Taiwan
Author contributions: Kuo YS wrote the manuscript; Kuo YS, Lin KH, Chen YY, Tsai YM, and Wu TH attended the postoperative care; Kuo YS and Huang HK performed the donor-lung graft harvest surgery; Kuo YS and Huang TW performed the sequential double lung transplantation in this case; All authors have read and approved the final manuscript.
Informed consent statement: After obtaining approval from the Institutional Review Board (IRB) at Tri-Service General Hospital, the study (IRB number: C202415028) was conducted in accordance with the approved protocol. The IRB approval process ensures that the study adheres to ethical guidelines and protects the rights and welfare of human subjects. The study participant provided informed consent before enrollment, and all data collected were kept confidential and handled in accordance with data protection regulations.
Conflict-of-interest statement: All authors declare that there are no conflict of interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tsai-Wang Huang, MD, PhD, Professor, Surgeon, Surgical Oncologist, Division of Thoracic Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, No. 325 Section 2, Chenggong Rd, Neihu District, Taipei 114202, Taiwan. chi-wang@yahoo.com.tw
Received: May 14, 2024
Revised: October 2, 2024
Accepted: October 15, 2024
Published online: March 18, 2025
Processing time: 197 Days and 5.6 Hours
Core Tip

Core Tip: The first successful experience indicated intravenous immunoglobulin as a valuable adjunct in managing severe coronavirus disease 2019 infection complicated with severe acute respiratory distress syndrome and septic shock in a lung transplant recipient.